$20.03
0.251.26%
At Close: -
$19.79
-0.24-1.18%
After Hours: 2:56 PM EDT
15 minutes delayed
Rocket Pharmaceuticals
RCKTNASDAQ
Rocket Pharmaceuticals (NASDAQ:RCKT) Stock, Analyst Ratings, Price Targets, Predictions
Rocket Pharmaceuticals Inc has a consensus price target of $48.19, established from looking at the 50 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, Chardan Capital, and Needham on July 3, 2024, June 28, 2024, and June 28, 2024. With an average price target of $51.33 between Canaccord Genuity, Chardan Capital, and Needham, there's an implied 159.33% upside for Rocket Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Chardan Capital
Needham
Goldman Sachs
UBS
1calculated from analyst ratings
Analyst Ratings for Rocket Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/03/2024 | Buy Now | 102.08% | Canaccord Genuity | Whitney Ijem | $49 → $40 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 213.22% | Chardan Capital | Geulah Livshits | $62 → $62 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | 162.7% | Needham | Gil Blum | $53 → $52 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 167.75% | Needham | Gil Blum | → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 167.75% | Needham | Gil Blum | → $53 | Reiterates | Buy → Buy | Get Alert |
| 04/02/2024 | Buy Now | 97.02% | Goldman Sachs | Richard Law | → $39 | Initiates | → Neutral | Get Alert |
| 03/01/2024 | Buy Now | 172.8% | UBS | Colin Bristow | $56 → $54 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 152.6% | JP Morgan | Eric Joseph | $55 → $50 | Maintains | Overweight | Get Alert |
| 02/27/2024 | Buy Now | 228.37% | Cantor Fitzgerald | Josh Schimmer | $65 → $65 | Maintains | Overweight | Get Alert |
| 02/13/2024 | Buy Now | 167.75% | Needham | Gil Blum | → $53 | Reiterates | Buy → Buy | Get Alert |
| 01/31/2024 | Buy Now | 228.37% | Cantor Fitzgerald | Louise Chen | → $65 | Reiterates | Overweight → Overweight | Get Alert |
| 11/07/2023 | Buy Now | 167.75% | Needham | Gil Blum | → $53 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2023 | Buy Now | 228.37% | Cantor Fitzgerald | Josh Schimmer | → $65 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | Buy Now | 142.49% | Stifel | Dae Gon Ha | → $48 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 167.75% | Needham | Gil Blum | $60 → $53 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 137.44% | Canaccord Genuity | Whitney Ijem | $49 → $47 | Maintains | Buy | Get Alert |
| 08/11/2023 | Buy Now | 208.17% | Chardan Capital | Geulah Livshits | → $61 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 203.11% | Needham | Gil Blum | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 142.49% | Stifel | Dae Gon Ha | $53 → $48 | Maintains | Buy | Get Alert |
| 05/23/2023 | Buy Now | 203.11% | Needham | Gil Blum | → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2023 | Buy Now | 208.17% | Chardan Capital | Geulah Livshits | $63 → $61 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 76.82% | Raymond James | Steven Seedhouse | $33 → $35 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 203.11% | Needham | Gil Blum | → $60 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | 203.11% | Needham | Gil Blum | → $60 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | 218.27% | Chardan Capital | Geulah Livshits | $65 → $63 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | 203.11% | Needham | Gil Blum | → $60 | Reiterates | → Buy | Get Alert |
| 02/01/2023 | Buy Now | 127.34% | Morgan Stanley | Michael Ulz | → $45 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | 147.54% | SVB Leerink | Mani Foroohar | $50 → $49 | Maintains | Outperform | Get Alert |
| 12/23/2022 | Buy Now | 76.82% | B of A Securities | Greg Harrison | $38 → $35 | Maintains | Buy | Get Alert |
| 12/22/2022 | Buy Now | 152.6% | SVB Leerink | Mani Foroohar | $54 → $50 | Maintains | Outperform | Get Alert |
| 12/06/2022 | Buy Now | 172.8% | SVB Leerink | Mani Foroohar | $56 → $54 | Maintains | Outperform | Get Alert |
| 11/08/2022 | Buy Now | 167.75% | Canaccord Genuity | Whitney Ijem | → $53 | Initiates | → Buy | Get Alert |
| 11/07/2022 | Buy Now | 66.71% | Raymond James | Steven Seedhouse | $34 → $33 | Maintains | Outperform | Get Alert |
| 11/04/2022 | Buy Now | 203.11% | Needham | Gil Blum | $62 → $60 | Maintains | Buy | Get Alert |
| 11/01/2022 | Buy Now | 76.82% | BTIG | Yun Zhong | → $35 | Initiates | → Buy | Get Alert |
| 10/03/2022 | Buy Now | 228.37% | Chardan Capital | Geulah Livshits | $62 → $65 | Maintains | Buy | Get Alert |
| 10/03/2022 | Buy Now | 71.76% | Raymond James | Steven Seedhouse | $24 → $34 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | 203.11% | SVB Leerink | Mani Foroohar | $65 → $60 | Maintains | Outperform | Get Alert |
| 09/30/2022 | Buy Now | 278.89% | Evercore ISI Group | Joshua Schimmer | $65 → $75 | Maintains | Outperform | Get Alert |
| 09/27/2022 | Buy Now | 213.22% | UBS | Colin Bristow | $68 → $62 | Maintains | Buy | Get Alert |
| 08/09/2022 | Buy Now | 21.25% | Raymond James | Steven Seedhouse | $22 → $24 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 182.91% | Stifel | Dae Gon Ha | $67 → $56 | Maintains | Buy | Get Alert |
| 07/08/2022 | Buy Now | 11.14% | Raymond James | Timur Ivannikov | → $22 | Initiates | → Outperform | Get Alert |
| 07/06/2022 | Buy Now | 223.32% | SVB Leerink | Mani Foroohar | $66 → $64 | Maintains | Outperform | Get Alert |
| 05/20/2022 | Buy Now | 213.22% | Chardan Capital | Geulah Livshits | $60 → $62 | Maintains | Buy | Get Alert |
| 05/20/2022 | Buy Now | 233.43% | SVB Leerink | Mani Foroohar | $64 → $66 | Maintains | Outperform | Get Alert |
| 05/17/2022 | Buy Now | 213.22% | Needham | Gil Blum | $75 → $62 | Maintains | Buy | Get Alert |
| 02/24/2022 | Buy Now | 223.32% | SVB Leerink | Mani Foroohar | $62 → $64 | Maintains | Outperform | Get Alert |
| 12/15/2021 | Buy Now | 203.11% | Chardan Capital | Geulah Livshits | — | Maintains | Buy | Get Alert |
| 08/10/2021 | Buy Now | 213.22% | SVB Leerink | Mani Foroohar | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Rocket Pharmaceuticals (RCKT) stock?
The latest price target for Rocket Pharmaceuticals (NASDAQ:RCKT) was reported by Canaccord Genuity on July 3, 2024. The analyst firm set a price target for $40.00 expecting RCKT to rise to within 12 months (a possible 102.08% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rocket Pharmaceuticals (RCKT)?
The latest analyst rating for Rocket Pharmaceuticals (NASDAQ:RCKT) was provided by Canaccord Genuity, and Rocket Pharmaceuticals maintained their buy rating.
When was the last upgrade for Rocket Pharmaceuticals (RCKT)?
There is no last upgrade for Rocket Pharmaceuticals
When was the last downgrade for Rocket Pharmaceuticals (RCKT)?
There is no last downgrade for Rocket Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Rocket Pharmaceuticals (RCKT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rocket Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rocket Pharmaceuticals was filed on July 3, 2024 so you should expect the next rating to be made available sometime around July 3, 2025.
Is the Analyst Rating Rocket Pharmaceuticals (RCKT) correct?
While ratings are subjective and will change, the latest Rocket Pharmaceuticals (RCKT) rating was a maintained with a price target of $49.00 to $40.00. The current price Rocket Pharmaceuticals (RCKT) is trading at is $19.79, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.